No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RLMD240816C12500
- 0.18
- 0.000.00%
15min DelayClose Jul 22 15:50 ET
0.00High0.00Low
0.18Open0.18Pre Close0 Volume211 Open Interest12.50Strike Price0.00Turnover293.09%IV206.28%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.1480Delta0.0725Gamma23.00Leverage Ratio-0.0145Theta0.0003Rho3.40Eff Leverage0.0025Vega
Intraday
- 5D
- Daily
News
Institutional Investors Have a Lot Riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) With 48% Ownership
Express News | CORRECTION: (Reported June 18, 2024) Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Earlier, Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Keybanc rai
Relmada Therapeutics Price Target Cut to $2.00/Share From $3.00 by Goldman Sachs
Relmada Therapeutics Price Target Cut to $2.00/Share From $3.00 by Goldman Sachs
Comments
The recent purchase by Sergio Traversa indicates optimism about the company's future. Despite the company making losses, the insider transactions suggest confidence in a bright future for Relmada Therapeutics.
Insider Spends US$387k Buying More Shares In Relmada Therapeutics
$SPDR S&P Biotech ETF(XBI.US$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
14
1
Read more